Ascendis Pharma A/S announced that YORVIPATH (palopegteriparatide) is now commercially available by prescription in the United States for the treatment of hypoparathyroidism in adults. YORVIPATH is the first and only medicine approved by the U.S. Food & Drug Administration (FDA) for this condition.
Administered once-daily, YORVIPATH is a prodrug of parathyroid hormone (PTH [1-34]) designed to provide continuous exposure to active PTH over a 24-hour dosing period. This novel approach addresses the underlying cause of hypoparathyroidism, a debilitating hormone deficiency.
To support patient access, Ascendis has established a dedicated YORVIPATH team within its U.S. Ascendis Signature Access Program. This program offers comprehensive support, including clinical education, assistance with prior authorization and appeals, injection training, and co-pay assistance for eligible patients.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.